SPC Financial Inc. Purchases 122 Shares of Gilead Sciences, Inc. $GILD

SPC Financial Inc. lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,902 shares of the biopharmaceutical company’s stock after buying an additional 122 shares during the period. SPC Financial Inc.’s holdings in Gilead Sciences were worth $654,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Smallwood Wealth Investment Management LLC acquired a new position in shares of Gilead Sciences during the 1st quarter worth about $25,000. Activest Wealth Management lifted its stake in Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the last quarter. Goodman Advisory Group LLC acquired a new stake in Gilead Sciences in the 1st quarter valued at about $29,000. Colonial Trust Advisors lifted its stake in Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 213 shares during the last quarter. Finally, Core Alternative Capital lifted its stake in Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 241 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the transaction, the chief financial officer directly owned 159,555 shares of the company’s stock, valued at approximately $18,120,661.35. This trade represents a 1.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the transaction, the insider directly owned 114,168 shares in the company, valued at $13,532,333.04. This represents a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 77,000 shares of company stock valued at $8,853,430. 0.27% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several brokerages recently issued reports on GILD. Cantor Fitzgerald raised their target price on shares of Gilead Sciences from $129.00 to $135.00 and gave the company an “overweight” rating in a research note on Thursday. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. Citigroup raised their target price on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Wednesday, October 8th. Royal Bank Of Canada raised their target price on shares of Gilead Sciences from $98.00 to $100.00 and gave the company a “sector perform” rating in a research note on Wednesday, October 8th. Finally, UBS Group raised their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research note on Friday, August 8th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $118.08.

Gilead Sciences Trading Up 0.4%

Shares of GILD stock opened at $117.18 on Monday. The firm has a 50 day moving average price of $114.65 and a two-hundred day moving average price of $110.25. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The company has a market capitalization of $145.40 billion, a PE ratio of 23.34, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34. Gilead Sciences, Inc. has a 12-month low of $84.17 and a 12-month high of $121.83.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period last year, the business posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were issued a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. Gilead Sciences’s dividend payout ratio (DPR) is currently 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.